Galecto to lay off 70% of its workforce - announces plans to explore "strategic alternatives"
Biotech company Galecto has been in the mulling box since the company was forced to abandon its lead drug candidate at the end of August after a phase 2b study failed.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.